AIGH Capital Management LLC Sells 200,000 Shares of Personalis, Inc. (NASDAQ:PSNL)

AIGH Capital Management LLC trimmed its stake in Personalis, Inc. (NASDAQ:PSNL) by 5.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,799,064 shares of the company’s stock after selling 200,000 shares during the quarter. Personalis comprises about 6.9% of AIGH Capital Management LLC’s holdings, making the stock its 3rd biggest position. AIGH Capital Management LLC owned 5.38% of Personalis worth $21,959,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. JPMorgan Chase & Co. grew its stake in shares of Personalis by 2,827.0% in the 4th quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company’s stock valued at $34,000 after buying an additional 5,654 shares during the period. Olympiad Research LP acquired a new stake in Personalis in the fourth quarter valued at approximately $59,000. SG Americas Securities LLC bought a new stake in shares of Personalis during the fourth quarter valued at approximately $63,000. Raymond James Financial Inc. bought a new stake in shares of Personalis during the fourth quarter valued at approximately $64,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in shares of Personalis during the fourth quarter worth approximately $87,000. 61.91% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Craig Hallum started coverage on shares of Personalis in a research note on Monday, March 17th. They set a “buy” rating and a $8.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Personalis in a research report on Friday, February 28th. Lake Street Capital upped their target price on shares of Personalis from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Finally, Needham & Company LLC cut their price target on Personalis from $7.25 to $7.00 and set a “buy” rating for the company in a research note on Friday, February 28th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $7.80.

Personalis Price Performance

NASDAQ PSNL opened at $3.62 on Friday. The company has a fifty day moving average price of $4.60 and a 200-day moving average price of $4.79. The firm has a market cap of $319.51 million, a price-to-earnings ratio of -2.15 and a beta of 1.73. Personalis, Inc. has a 1 year low of $1.14 and a 1 year high of $7.20.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.09. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The business had revenue of $16.80 million during the quarter, compared to the consensus estimate of $15.48 million. On average, research analysts anticipate that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.